Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

196.50 +1.80 (+0.92%)
Streaming Delayed Price Updated: 11:15 AM EST, Nov 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Charles River Laboratories Intl

< Previous 1 2 3 4 Next >
The 3 Most Undervalued Tech Stocks to Buy Now: November 2023
Growth stocks are rallying but there are still bargains to be found. These three top tech picks can reward long-term investors. 
Via InvestorPlace
Expert Ratings for Charles River
Via Benzinga
Charles River Labs Q3 Revenue Jumps 4% Despite Softer Client Spending, Narrows Outlook
Charles River Laboratories International Inc (NYSE: CRL) reported third-quarter (Q3) sales of $1.03 billion, an increase of 3.8% Y/Y, beating the  
Via Benzinga
8 Analysts Have This to Say About Charles River
Via Benzinga
Q4 Stock Predictions: 3 S&P 500 Stocks Ready to Soar
S&P 500 stocks are sliding amid a worrying interest rate environment. However, these three can buck the current downtrend. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
What 5 Analyst Ratings Have To Say About Charles River
Via Benzinga
Steer Clear of Outrageously Valued VinFast Stock. 3 EV Stocks to Buy Instead.
VinFast stock has gotten inflated since its blank-check merger in early August. Check out these three EV stocks instead. 
Via InvestorPlace
WeWork's Journey From $47B Valuation To Possible Bankruptcy, Mastercard and Visa Reassess Ties with Binance Card, Hawaiian Electric Accused Of Jeopardizing Investigation Of Maui Wildfires: Today's Top Stories
Wall Street Journal 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Endangered Horseshoe Crabs Vital In Medical Research, Charles River Lab Commits To Enhanced Protection
Charles River Laboratories International Inc (NYSE: CRL) has joined hands with four significant entities in a pioneering move to amplify protections for the horseshoe crabs and the red knots bird... 
Via Benzinga
4 Analysts Have This to Say About Charles River
Via Benzinga
Charles River: Q1 Earnings Insights
Via Benzinga
Will Chart Analysts Notice Bad Omen on Charles River's Chart
Via Benzinga
B of A Securities Maintains Buy Rating for Charles River: Here's What You Need To Know
Via Benzinga
US Stocks Edge Lower; Charles River Earnings Top Estimates
U.S. stocks were mostly lower this morning, with the Nasdaq Composite falling more than 50 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.03% to 35,303.64 while the... 
Via Benzinga
Lyft, Disney And 3 Stocks To Watch Heading Into Wednesday
With U.S. stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Investor Sentiment Declines After Moody's Downgrades Credit Ratings Of Banks
The CNN Money Fear and Greed index showed a decline in overall sentiment among U.S. investors on Tuesday. U.S. stocks closed lower on Tuesday after Moody's downgraded the credit ratings of several US... 
Via Benzinga
Buy Alert: 3 Healthcare Stocks Nearing Super Attractive Entry Points
Explore the resilience of healthcare stocks that are demonstrating signs of recovery, with robust long-term growth potential ahead. 
Via InvestorPlace
Analyst Ratings for Charles River
Via Benzinga
Why Charles River Stock Is Plunging Today
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023
Via Benzinga
BlackRock To Rally Around 22%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc raised the price target for BILL Holdings, Inc. (NYSE: BILL) from $110 to $140. Keybanc analyst Josh Beck maintained an Overweight rating. BILL Holdings shares fell 2.3% to $113.00 in... 
Via Benzinga
3 Cheap Stocks to Buy Before They Bounce Back
Afraid of missing out on the big market rally? These three cheap stocks to buy are still strong options, so hop on board. 
Via InvestorPlace
3 Long-term Healthcare Stocks to Add to Your Portfolio
These long-term healthcare stocks should benefit from the global surge in spending for life-improving pharmaceutical drugs, therapies, and medical devices. 
Via InvestorPlace
3 DNA Stocks to Buy for the Synthetic Biology Revolution
Synthetic biology is a growing industry. The big winners will be DNA stocks that are able to sell to everyone, not just a small niche. 
Via InvestorPlace
3 Healthcare Stocks With Huge Growth Potential
It's been a tough time for the tech industry. So consider these healthcare growth stocks to buy now instead. 
Via InvestorPlace
$39M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 23, 2023
Via Benzinga
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Windtree Therapeutics Inc (NASDAQ: WINT) shares jumped 75.3% to $0.2921. Windtree Therapeutics has been granted U.S. patent number 11,583,540 titled "Istaroxime-Containing Intravenous... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.